Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Clinical Trial
Official title:
The Effectiveness of Phytotherapy in the Treatment of SARS-COV2 (COVID-19)
Quercetin is one of the flavonoids. Quercetin as well as rutin are recognized to be among the most active of the flavonoids. It is to quercetin that several medicinal plants, including ginkgo and St. John's Wort, owe part of their therapeutic effects. Often combined with vitamin C in supplements, it improves absorption by the body and delays its elimination. Quercetin is extracted from a variety of plant sources, including the onion peel and seeds and pods of Dimorphandra mollis, a tree in the legume family native to South America. At present, there is no scientific data to demonstrate the effectiveness of herbal medicine, regardless of the plant, to prevent or treat COVID-19. On the other hand, some plant-based food supplements have anti-inflammatory or immunomodulatory properties that may disrupt inflammatory defense mechanisms useful in fighting infections, and in particular against COVID-19.
Type of study: a randomized, double-blind study using the Quercetine in the treatment of patients with SARS COV2 (covid-19) Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America. Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies. History on quercetin In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04768998 -
Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)
|
||
| Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 | |
| Terminated |
NCT04940871 -
Study to Assess the Efficacy and Safety of Favipiravir-HU
|
Phase 2 | |
| Completed |
NCT04588363 -
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
|
||
| Completed |
NCT05249816 -
Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine
|
Phase 3 | |
| Recruiting |
NCT04863547 -
Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection
|
||
| Terminated |
NCT04389840 -
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
|
Phase 2/Phase 3 | |
| Completed |
NCT04933929 -
Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (COVID-19) Status (Positive or Negative) During Hospitalization
|
N/A | |
| Completed |
NCT04725084 -
Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
|
||
| Withdrawn |
NCT05545319 -
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
|
Phase 2 | |
| Terminated |
NCT04391309 -
COVID-19 and Anti-CD14 Treatment Trial
|
Phase 2 | |
| Completed |
NCT04343261 -
Convalescent Plasma in the Treatment of COVID 19
|
Phase 2 |